Objectives ICIs have been approved and are routinely administered regardless of
performance status (PS), despite randomized clinical trials of ICIs alone or combined with …

Simple Summary v-Ki-ras2 Kirsten rat sarcoma viral oncogene (KRAS) is the most common
driver in NSCLC, and targeting oncogenic KRAS is a major challenge in the treatment of non …

Quantifying the effectiveness of different cancer therapies in patients with specific tumor
mutations is critical for improving patient outcomes and advancing precision medicine. Here …

Background Primary analysis of the phase III study WJTOG 3405 demonstrated superiority of
progression-free survival (PFS) for gefitinib (G) in patients treated with the epidermal growth …

Secondary mutation, T790M, conferring tyrosine kinase inhibitors (TKIs) resistance beyond
oncogenic epidermal growth factor receptor (EGFR) mutations presents a challenging unmet …

Objective Panel-based next-generation sequencing (NGS) is increasingly used for the
diagnosis of EGFR-mutated non-small-cell lung cancer (NSCLC) and could improve risk …

The mechanisms leading to immune escape of melanoma have been largely investigated in
relation to its tumour immunogenicity and features of inflamed microenvironment that …

Lung cancer, the most frequently diagnosed cancer worldwide, is the leading cause of
cancer-associated deaths. In recent years, significant progress has been achieved in basic …

Background Osimertinib exhibits good efficacy in patients with T790M-positive non-small
cell lung cancer (NSCLC) and acquired resistance to epidermal growth factor receptor …

Objective Lung cancer is increasingly recognised as a heterogeneous disease. Recent
advances with targeted therapies for lung cancer with oncogenic mutations have greatly …